Fusion Antibodies PLC
LSE:FAB
Fusion Antibodies PLC
Long-Term Debt
Fusion Antibodies PLC
Long-Term Debt Peer Comparison
Competitive Long-Term Debt Analysis
Latest Figures & CAGR of Competitors
Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Fusion Antibodies PLC
LSE:FAB
|
Long-Term Debt
£30k
|
CAGR 3-Years
-41%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Long-Term Debt
£37.3m
|
CAGR 3-Years
20%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
O
|
Open Orphan PLC
LSE:ORPH
|
Long-Term Debt
£737k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Diaceutics PLC
LSE:DXRX
|
Long-Term Debt
£1.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
Ergomed PLC
LSE:ERGO
|
Long-Term Debt
£1.4m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
327%
|
CAGR 10-Years
N/A
|
|
hVIVO PLC
LSE:HVO
|
Long-Term Debt
£12.2m
|
CAGR 3-Years
77%
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
See Also
What is Fusion Antibodies PLC's Long-Term Debt?
Long-Term Debt
30k
GBP
Based on the financial report for Sep 30, 2023, Fusion Antibodies PLC's Long-Term Debt amounts to 30k GBP.
What is Fusion Antibodies PLC's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
3%
Over the last year, the Long-Term Debt growth was -88%. The average annual Long-Term Debt growth rates for Fusion Antibodies PLC have been -41% over the past three years , 3% over the past five years .